Digital Therapeutics Aided 83% Of Patients In Keeping Vitals Under Normal Range Claims Study
Lupin Digital Health (LDH), a digital therapeutics platform, has unveiled the results of a study in India, showing the efficacy of digital therapeutics (DTx) among patients with the acute coronary syndrome (ACS) and post-percutaneous coronary interventions.
The one-year-long study aimed to evaluate the efficacy of LDH's digital therapeutics platform, Lyfe, on cardiovascular events, rehospitalisation, medication adherence, vital sign monitoring, and lifestyle changes among heart patients. The study claims that during the 90-day interim analysis, patients enrolled in the program demonstrated significant improvement, with 90 per cent adhering to the recommended medication, diet, and exercise regimen. 83.3 per cent of patients maintained their vital signs within the normal range, and no re-hospitalisations occurred during the first 30 days of enrolment.
"As an interventional cardiologist, I am happy to see such positive and promising early results of the study, with more than 90 per cent of patients adhering to the recommended medication, diet, and exercise regimen prescribed by us. By leveraging evidence-based technologies like digital therapeutics, we are revolutionising the way we deliver healthcare to our patients. While this is an excellent start, we intend to undertake extensive clinical studies and foster collaborative efforts among all healthcare stakeholders to establish digital therapeutics in cardiology and unlock their full potential," said Dr. Abhijeet Palshikar, Interventional Cardiologist, Pune.
"We are excited to share the positive outcomes of India's first digital therapeutics study. The study's outcomes showcase the effectiveness of our evidence-based and comprehensive heart care program in ensuring high adherence and low re-hospitalisation for patients,” said Sidharth Srinivasan, CEO, Lupin Digital Health.
